A Study to Evaluate INT101 in Healthy Adults for the Prevention of Norovirus Gastroenteritis

Inclusion Criteria: * Healthy adults aged 19 to 48 years (inclusive) as of the screening visit * Body Mass Index (BMI) of 18.0 to 30.0 kg/m\^2 (inclusive) at screening * Women and men of reproductive potential willing to use a highly effective contraceptive method (hormonal contraceptives, intrauterine device/system, or sterilization) from 30 days prior to the first investigational product administration through 2 months after the last administration * For female participants, a negative pregnancy test result at screening * Agreement not to donate blood or receive blood transfusion during the study period * Judged to be healthy by the investigator based on clinical judgment, medical history, and physical examination at screening * Able to understand the purpose of the study and voluntarily provide written informed consent to participate and comply with study restrictions Exclusion Criteria: * Autoimmune disease (e.g., rheumatoid arthritis, hypothyroidism) at screening * Uncontrolled hypertension (BP not controlled below 140/90 mmHg, or 130/80 mmHg if diabetic, despite maximal doses of 3 or more antihypertensive agents) or diabetes (HbA1c \>7.0%) * Neurological disease (e.g., epilepsy, seizure, Guillain-Barre syndrome) * Asthma * Uncontrolled bleeding disorder or receipt of anticoagulant therapy * History of immunodeficiency or immune dysfunction * History of malignancy within 5 years prior to the first dose (excised skin lesions or basal cell carcinoma successfully treated with no recurrence for 3 or more years may be enrolled at investigator discretion) * Suspected or history of substance abuse prior to study participation * Significant alcohol consumption (21 or more drinks/week for men, 14 or more drinks/week for women) or excessive smoking (20 or more cigarettes/day) within 1 month prior to the first dose * History of gastrointestinal illness (e.g., enteritis, diarrhea, abdominal pain, vomiting) within 14 days prior to the first dose * Positive result for HIV antigen/antibody, Hepatitis B surface Antigen (HBsAg), Anti-Hepatitis C Virus (Anti-HCV), or syphilis at screening * Participation in another clinical trial involving an investigational drug or device within 6 months prior to the first dose * Receipt of immunoglobulin or blood products within 6 months prior to the first dose, or planned receipt during the study * Receipt of immunosuppressive or immunomodulatory agents (e.g., Azathioprine, Cyclosporine) within 6 months prior to the first dose * Receipt of cytotoxic chemotherapy that may affect immune function * History of radiation therapy * Receipt or planned receipt of any vaccine other than the investigational product within 4 weeks before or after each investigational product administration * High fever (38C or above) within 3 days prior to the first dose, or clinically significant suspected acute infection * Use of analgesics or antipyretics within 1 day prior to investigational product administration * Chronic steroid use (Prednisolone more than 10 mg/day for more than 14 consecutive days), unless discontinued for 6 months or more prior to screening (topical, nasal, inhaled, or ophthalmic steroids permitted regardless of dose) * Inflammation at or near the planned injection site * Planned blood donation during the study period * Pregnant or breastfeeding women * History of serious adverse event, allergy, or hypersensitivity reaction related to vaccination * History of organ or hematopoietic stem cell transplant prior to study participation * Clinically significant abnormal laboratory test result at screening * Suspected or history of alcohol abuse * Known hypersensitivity to the investigational product or its components * Chronic underlying disease, congenital disease, or mental illness judged by the investigator to interfere with study conduct or completion * Any other condition judged by the investigator to make the participant unsuitable for the study